pharma · Hepatocellular Carcinoma · Obesity
Hospital Authority
Hospital Authority, Hong Kong
Hospital Authority, Hong is a pharma organization headquartered in CN. Primary therapeutic focus areas include Hepatocellular Carcinoma, Obesity, Acute Kidney Injury, Nasopharyngeal Carcinoma, Coronary Artery Disease. No
Hospital Authority Building, 147B Argyle Street, Kowloon, Hong Kong, 852, HK, CN HQ
1991 Founded
12,669 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Hospital Authority Building, 147B Argyle Street, Kowloon, Hong Kong, 852, HK, CN
- Founded
- 1991
- Employees
- 12,669
- Programs
- 322
- Drugs
- 301
- Patents
- 0
INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 μg
Phase 1 · mab · COVID-19 Pandemic
INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 μg for COVID-19 Pandemic is a Phase 1 program (mab) at Hospital Authority, Hong Kong with 1 ClinicalTrials.gov record(s).
Internal code UNAIR-MP-INAKTIF-R-010
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Hospital Authority, Hong Kong
- Phase
- Phase 1
- Modality
- mab
- Indication
- COVID-19 Pandemic
- Status
- active
- Trials
- 1